Erythropoiesis-Stimulating Agents — Time for a Reevaluation
Unger EF, Thompson AM, Blank MJ, Temple R. N Engl J Med. 2010 Jan 21;362(3):189-92
This NEJM “Perspectives” article from the Food and Drug Administration discusses the data driving a need to re-evaluate the use of ESAs in the treatment of anemia due to chronic kidney disease.
Related Articles:
- The FDA’s Perspective on the Risk for Rapid Rise in Hemoglobin in Treating CKD Anemia: Quo Vadis
- Stage IV Chronic Kidney Disease
- Does TREAT Give the Boot to ESAs in the Treatment of CKD Anemia?
Recent Comments